Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery
Phase 1
Active, not recruiting
- Conditions
- Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resectionMedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864Therapeutic area: Phenomena and Processes [G] - Metabolism [G03]
- Registration Number
- CTIS2024-511171-15-00
- Lead Sponsor
- Celgene Corp.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 216
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method